Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Oriola, Webcast, Q1'26

By Inderes4/29/2026, 7:00 AM
Oriola

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:01 - 01:00

Good morning everyone and a warm welcome to Oriola Q1 Audiocast. I am from Oriola Investor Relations. With me today I have our CEO Katerina Gabrielsson and CFO Mats Danielsson. We will start with Katerina's presentation followed by Mats' financial review. After the presentation, we will open up for your questions. As a kind reminder, in the Q&A, we will focus on questions relating to Oriola business and financial performance. As always, you can start posting questions to us already during the presentation through the chat. Finally, please note that we are recording this Audiocast and a recording will be available on our website later today. Before handing over to Katerina, here is the disclaimer that we all should be aware of. And now, without further ado, Katerina, please go ahead.

Katerina Gabrielsson
01:01 - 11:19

Thank you. And also welcome on my behalf. And if you look at the first quarter, we can see that the demand for Oriola distribution services has remained strong. It has been supported by continued engagement with existing customers and also a solid pipeline of new customer opportunities in the wholesale business. The positive development from last year has continued building on the actions and improvements implemented in 2025. Last year, we said that we were investing in this business, and we can also now start to see the results. We have strengthened our footprint in the growing retail channel, and we have also expanded the sales channel mix for animal health. And growth has also continued in the e-commerce channel. In the first quarter, Oriola's net sales were growing by 10.7% to €49.8 million, and adjusted EBITDA was €7.7 million, which corresponds to an adjusted EBITDA margin of 15.4%. In Finland, we have also started the construction of Oriola's new, highly automated state-of-the-art distribution center in Järvenpää, and has started well and is progressing as planned. In parallel, the investments to renew our ERP and warehouse management system continue. As we announced last time, we have integrated the first phase in Sweden during the end of last year. And we are now planning for the second deployment in Sweden. Our supply chain operations have remained stable during the quarter, and operations at Enköping and Mankkaa sites have performed well, while volumes in Mankkaa central warehouse were high. Also in the first quarter. This is partly reflecting customers in our distribution business building inventories in Oriola warehouses at the distribution center. We have continued to improve in ways of working, and we have enhanced operational efficiency. An improvement in filling rate in our totes has reduced the number of daily trucks, and has also been supporting the cost control that we have in the supply chain area. This is also contributing to environmental objectives, as fewer totes will result in a smaller environmental footprint in our transportation. In March, we also announced that we will make a €5 million investment in Enköping distribution center in automation. This will further increase the level of automation, improving efficiency and competitiveness, and strengthening our ability to respond to market growth and evolving customer requirements expected in the future. Then, if you look at the joint venture company Kronans Apotek from Oriola point of view. We are not satisfied with Kronans Apotek's performance in the first quarter. There will now be corrective actions to achieve the desired performance. Kronans Apotek is therefore launching initiatives that are focused on both revenue and cost efficiency. On the revenue side, efforts are directed towards strengthening commercial execution. It's also about optimising product mix and enhancing in-store and digital sales performance. In parallel, a cost optimization programme is being launched with a particular focus on reviewing the head office functions and potentially adding additional synergies from the recent integration that was finalized at the end of last year, but some parts are, of course, still to be done. This includes identifying and eliminating inefficiencies, ensuring an appropriate cost base going forward, and also clarifying which costs are structural versus temporary in nature. These actions are aimed at improving profitability, strengthening operational discipline, and positioning Kronans Apotek for more sustainable performance in the coming quarters. Next, let's look at the operating environment. Regarding the operating environment, we can see that in the first quarter, the value of the pharmaceutical distribution market grew in Sweden by 12.5%, while the growth was more modest in Finland by around 4%. We can also see that the geopolitical situation and the market share in both countries were stable. Let's add that one. Also, regarding the geopolitical situation, we observe increased uncertainty in the operating environment. Oriola is affected mainly by the higher fuel prices and also inflationary pressure. Our aim is to pass these costs on to our customers, and that is something we are working on for the coming quarters and months. We'll come back to this later, but we can say that for Q1, we haven't seen as many cost increases as was most likely expected from other sources; meanwhile, pharmaceutical companies continue to build inventories, as I mentioned before, to ensure the availability of pharmaceuticals. And this is a way, of course, to address the geopolitical situation. From our customer point of view. In advisory services, we see that we are affected by the situation with more cautious customers. And they are more cautious when it comes to decision-making. The lead times are longer, and it's significantly longer even. And it's affecting both the availability of new medicines in Europe. And that's also affecting, of course, us when it comes to advisory and to some extent, maybe in the future. Also in the pharmaceutical distribution, consumer confidence is weak in both Finland and Sweden compared to the normal levels. During the first quarter, we also announced a change in the financial reporting. And I want to add it already here, even if I know that Max will come back to this later. When we come to the financial matters, Oriola ensures safe and efficient distribution of pharmaceutical and health products. But we are fundamentally a service company offering value-adding logistics and also advisory services. And we also have a wide portfolio of health products. Our aim is to be more transparent towards you and also make it easier for you to understand what we are doing. And that's why we have now changed the revenue recognition policy and also started to use new segments. When I now go to the segments, you will see these segments for the first time. And the first segment that we have is the Services segment. And the Services segment is structured somewhat differently from what we had before. Today it consists of the distribution of pharmaceuticals. It also includes the value-adding services and parallel import in the Nordics. This segment also includes the advisory services and the commercial data solutions. So everything that we see where we have a service fee is part of now this segment. In this segment, the net sales during the quarter increased by 3.7% and landed on €36.6 million. The growth was driven by positive development in the distribution of pharmaceuticals in Finland and Sweden, as well as continued high volumes in the parallel import in Sweden. And I can also add here that this product mix is affecting our profitability, because parallel import has a lower margin compared to the rest of the pharmaceutical distribution. Growth was then supported by higher volumes, especially in the specialty flows that we have, and that is vaccines, it's exports and it's also animal health, and also by the overall market growth, particularly in Sweden. Advisory services, though, have had a slow start of the year, resulting in a decline in net sales compared with the previous year. And this is attributable to the overall geopolitical situation, which is affecting the segment. Adjusted EBITDA decreased to €8.8 million, with an adjusted EBITDA margin of 22%. The reduction was mainly due to the weak performance in the advisory services and also the product mix that I mentioned earlier. Next, we will move on to the Products segment. The other segment that we then have. And this is also the first time that we are now talking about this one. And that's the Products segment. The product segment consists of wholesale of traded goods and also over-the-counter products like painkillers. This also covers our own brands and the specialized medicines that we have in Finland and Sweden. The segment also includes the dose dispensing business in Finland. The net sales in this segment were growing by 9.6% to €15.4 million. The growth was supported by both the wholesale and the dose dispensing business in Finland. The Finnish wholesale business has continued the positive developments that started at the end of last year. That is supported by the expansion in the retail channel and also the continuous development of own brands. Sales of specialised medicines in Sweden were lower than in the comparison period. Adjusted EBITDA amounted to €2.1 million, with an adjusted EBITDA margin of 13.9%. The improvement was driven by the wholesale and the dose dispensing businesses in Finland. And with this, we will then go on to the Financial Review.

Mats Danielsson
11:21 - 26:19

Thank you Katerina, and welcome from my part also. This is now, as Katerina said, the first quarter we report with the new revenue recognition principles. And we believe that this new reporting will improve the transparency of our financial reporting and the understanding of our business logic. We have looked at and judged the distribution customer contracts and reclassified Oriola as an agent in these contracts. This has had an impact on net sales, and we will now be recognizing net sales on a net basis. So this is the only change in the pharmaceutical company contracts that we have. It's not a change to our own business. So, not all contracts have been reclassified. This has, of course, had an impact on the segments due to this. And we now have the two segments that Katerina mentioned: the Services segment, which is based on a service fee, and the Products segment, where there is no change in revenue recognition. If we then look at the segments, the Services segment is distribution of pharmaceuticals. We are distributing about 300 million packs per year. We have 4 billion in invoicing that we perform as a service to the pharmaceutical companies. This segment also, of course, includes services that we do to these same companies. And then we have parallel import and advisory services are included. So it's a big invoicing, but now the net sales have declined. That is more related to the service fee that we invoice. So it's a huge pass-through margin. And, with net sales being smaller, the Product segment is where we have the ownership of the products. The risk is in our hands, and we have the products in our own inventory also. The product segment, in a big picture, includes the wholesale and the dose dispensing business in Finland. The product segment also includes now for Q1 2025. It includes the Swedish Dose Dispensing business. We have tried to open that up also in the different tables and comments so that it's clear what is what. Then, if we go to the numbers, invoicing grew by 8.1% from 1 billion. This is then mainly the pass-through where we invoice on behalf of the customers. We had a decline in net sales. This is mainly due to the fact that we had the Swedish dose dispensing business in the first quarter last year. If we exclude that, we have a growth of10.7%. There is an FX impact of the Swedish krona that has strengthened during the same time. So approximately two percentage points of the 10.7% is affected by the FX. Svensk dos AB was only included in the first quarter last year. It was sold on the 1st of April. If you look at the development on net sales, we can say that it's coming both from the Services and Products segments. Especially the distribution services have been performing well both in Finland and Sweden. And we have a good growth in wholesale and also in the dose dispensing. There is also good growth in the dose dispensing business and in parallel import. Then if we look at the adjusted EBITDA, we have an improvement from 7.5 million to 7.7 million. It's mainly driven by the product segment. We have an adjusted EBITDA margin of 15.4% compared to 14.8%. If we exclude the dose dispensing business in Sweden, it's slightly declining. This is mainly due to the impact by the parallel import and the slow start for the advisory business. In the adjusting items, we have 2.4 million, a bit more than last year. It was 1.6 million last year. And that is related to the ERP project. As Katerina said, we have a very small impact from, for example, fuel price increases and costs for the quarter. And Järvenpää. Just a reminder that we have started to build in Järvenpää. And those costs are not shown as a lease agreement. So we are not having those costs before we move into the facilities or start producing or delivering there. Then if you go to the services segment. Good growth in distribution, specialty flows, and parallel import; advisory services. Slow and declining slightly. And we can see that the invoicing is growing 8.5%, net sales growing only 3.7%, on top of the slow start of the advisory services. It's good to remember that we have pricing that also affects why it doesn't always follow the invoicing. We have margin-based and transaction-based pricing towards the customers, which will, of course, have an impact on the development of the net sales in comparison to the invoicing. If we look at the adjusted EBITDA, it is slightly declining. And that is mainly affected by the decline in net sales from advisory services and in the EBITDA percentage. The parallel import also has an impact due to the fact that it's not as profitable as the other services. If we go to the product segment. This has been performing well. Overall. Both the wholesale and and the dose dispensing business in Finland has been performing both very well. This is then where we have the ownership of the products we source and sell. We can see that net sales are declining. That's related again to the Swedish dose dispensing business. So, 9.6% was the growth without the dose dispensing business. EBITDA grew from 1 million to 2.1 million. The EBITDA margin is now at 13.9%. So we are starting to come up to the right level in a way that it should be in this product business. Then if we look at the development of the result all the way down to the net profit, EBITDA was slightly lower than last year, mainly related to the adjusting the cost for the ERP and the adjusting items. If we look at the depreciations, we had a Svensk dos AB impairment last year, which increased the impairment. The impairment was 8.8. This year, we have now accelerated the depreciations of some Mankkaa assets and will have some more depreciations until we move to Järvenpää. Looking at the EBIT improving from last year, and of course, the share of result in the joint venture was a disappointment, -2.3 million, and we ended up in a profit for the period of -2 million. Then if we look at the cash flow, the free cash flow was negative. This is mainly related to the change in the working capital. We have really large payments coming in, and we had a few payments coming in a day or two days late, which affected the. The negative change in working capital of 20 million. The investment of 5.4 million is mainly related to the. To the acquisition of the land area in Järvenpää. And that's the only part that is affecting us. We bought the land ourselves for the facilities there. Net debt. No big change. Slightly impacted by the working capital and the free cash flow. No more comments on that. Then we have the equity ratio and gearing; the equity ratio was impacted slightly, mainly by the negative impact on the adjusting items again. And the result from the JV, and we can see that the gearing was also impacted by the negative cash flow. And then if you look at this, it was a weak quarter for Kronans, a disappointment for us regarding profit. All lines are lower than 2025. Most important, they are now starting an initiative to focus on growth and cost cutting, and that, in the plan, will improve the profitability starting already from quarter two onwards. And the outlook is the same. We expect the adjusted EBITDA to increase from the previous year. And the previous year was 35.1 million. So that was unchanged from last time. And then we also communicated the new financial targets. Both of these are, of course. Set to drive profitability. First, we need to grow. We have set a target to grow at least 5%. We know that we are growing more right now, but we also know that over time, this growth has not always been sustained. So, if in our strategy, we are aiming at 5% at least, then we have the efficiency target: adjusted cost to net sales. This is a driver to improve on EBITDA. We need to manage our cost base and see that we get the pass-through margin from the growth that we have. We have also now put it at 75%. Last year, we were at 82.6%. And now for the first quarter, we are at 85.2%. The first quarter does not fully reflect the full year, but there is also a timing issue. But we have improved from 2024 to 2025. We have also improved now quarter on quarter from 2025 to 2026. Then we have also a new dividend policy, partly new, partly old. We do not change the two-thirds of the net profit. What we have included is that the result from the JV is excluded. And then, of course, there's a disclaimer to evaluate the financial status or situation when dividends are paid. Then there was a decision by the board to initiate a share buyback program. Will now be initiated. Now, a maximum of 1 million shares and a maximum of 1.5 million are to be used. Thank you Max.

Katerina Gabrielsson
26:24 - 27:19

Thank you Mats. And with this, we will summarize the key takeaways. We had a really good start to the year. Both net sales and adjusted EBITDA were meeting our expectations. Supply chain operations have been stable, and we have also invested in automation at the distribution center in Enköping to better get efficiency for the future. And I would also really like to welcome you all to join our Capital Markets Day. That is quite soon. Coming up, it's already on the 12th of May. And in that, we think that we can then also give even more clear insights into what we're doing and transparency for the future. But with that, we conclude our presentation. And I can see that there have been some questions coming in. So, let's see, it's a little bit small for me to see.

Unknown 1
27:19 - 27:56

So good. So thank you, Katerina and Mats for your presentations. And, as a reminder, please use the chat to send in your questions. And in the Q&A, we will focus first on the questions relating to Oriola business and financial development. And we already have some questions. Let's kick off. So, relating to the parallel import. So could you explain more in detail why product mix impact from parallel import has negative impact on adjusted EBITDA.

Mats Danielsson
27:56 - 28:21

Mats, it does not have a negative impact on the EBITDA, but it has an impact on the EBITDA percentage. So the volume goes up, but the profitability is a bit lower. So if there's a mix change, then it will compare to the previous period. It will show an EBITDA percentage that is lower.

Unknown 1
28:22 - 28:37

All right. Good. And then, relating to the cost. So could you comment on a 25% increase in group administration and other costs. Will this trend continue the whole year?

Mats Danielsson
28:38 - 29:07

This is not the trend. And it's partly because we have had many large internal projects ongoing, and partly related to the phasing of those costs. We don't have a plan for costs to be growing. The cost would not be growing. Then we also see that there's an FX impact on the cost side, as well as on the sales side. But I think the most important message is that this is not a trend.

Katerina Gabrielsson
29:08 - 29:19

I can agree to that. We have talked about strict cost control during quite many quarters. And that is still there. So, it is exactly not a trend.

Mats Danielsson
29:19 - 29:20

And we have continued our efforts.

Katerina Gabrielsson
29:20 - 29:21

Strict cost is maintained.

Mats Danielsson
29:21 - 29:27

Control, and we have a new financial target that focuses exactly on the cost side also.

Katerina Gabrielsson
29:27 - 29:28

So good.

Unknown 1
29:29 - 29:44

Then a question related to the Services segment. So, if the advisory business had performed as in the comparison period, would the Services segment's profitability have been above or below the comparison period?

Mats Danielsson
29:48 - 30:02

We don't comment specifically on the advisory business as such, as a separate entity. But we would have been closer to last year's numbers if it had performed as it did last year. Yes.

Katerina Gabrielsson
30:03 - 30:15

You can say in that one that advisory services have a higher margin than the other parts of this segment. So that's a little bit something for you to note.

Unknown 1
30:15 - 30:41

Then there are a couple of questions relating to the financial targets, and we will take those. But of course, there will be more information about those also in the CMD. So what kind of costs are included in your new efficiency target? Does this mean costs at an EBIT or EBITDA level? And do these costs also include group administration costs?

Mats Danielsson
30:42 - 30:54

Yes, it includes all the costs. That includes freight. It includes the operational costs and administration costs and all the way down to EBITDA.

Unknown 1
30:55 - 31:08

Good. And then continuing on that. So in the financial targets, is there a reason why you measure costs to sales instead of, for instance, the EBITDA margin?

Mats Danielsson
31:09 - 31:28

We have actually chosen to look at the cost to sales because that's the driver of EBITDA. So we find it relevant to focus on the driver of improving EBITDA and not EBITDA as such. Of course, it will give the result on EBITDA if we improve on this.

Unknown 1
31:29 - 31:47

And there's one more question. I think you already answered this. But just in case you want to add something. So the 75% cost to sales target is this equivalent to 25% adjusted EBITDA margin. Or what do you mean by these costs?

Mats Danielsson
31:47 - 32:26

I have not yet calculated exactly what that is in relation to the EBITDA margin. It's of course that we might have a higher cost, yet it's always the cost in relation to sales and the EBITDA to sales. So we have focused more on where we end up if our costs are below 75% in relation to sales, which is actually our strategic target.

Katerina Gabrielsson
32:27 - 32:27

Yep.

Unknown 1
32:28 - 32:38

And then one more question relating to this efficiency target. And the costs. Are our leasing costs of Järvenpää included?

Mats Danielsson
32:39 - 32:53

The leasing cost for Järvenpää. For Järvenpää will be. We will book that as an asset in our balance sheet, and it will be depreciated, and there will be an interest cost. So it's not included in this cost.

Unknown 1
32:53 - 33:08

Okay. Good. Thank you. So then continuing on to the dividend policy. So does your new dividend policy excluding JV results imply that you don't see the recovery as plausible any time soon.

Katerina Gabrielsson
33:11 - 33:48

I will say that we want to have the possibility to have Oriola as a separate company. And this is one way of showing that the dividend policy that we have is reflecting the results of Oriola. When we go into Kronans Apotek, we will work for recovery as soon as possible. And we will come back to this in more detail at the CMD. But it's absolutely. So, for us, Oriola is an owner of the joint venture company. It's important to make the recovery as soon as possible, as it also is for you to get a more clear opinion of us as a company.

Unknown 1
33:50 - 34:13

Good. Thank you. And we have one more question in the chat. So if you have any other questions, please post them through the chat so that we can take them. And it relates to the share buyback program. So how should we view the share buyback program in the light of your low equity ratio and aim to improve that?

Mats Danielsson
34:16 - 34:56

We see that this is a part of our distribution to our owners. And this serves the interest of shareholders; also, the amount is still fairly small, and, of course, we have it. We have, in relation to this, the dividend policy. And this is a combination that we all the time follow. And we also split the dividend now for the spring and autumn so that we follow the dividend policy. And see also how the equity ratio develops.

Unknown 1
34:59 - 35:32

Good. Thank you. So, looks like there are no more questions in the chat. And, thank you, everyone for joining us today. And as a reminder, and already mentioned, the CMD takes place on 12th of May and it's a hybrid event. And you can follow the event live through a webcast. And, in the meantime, if you have any questions, please don't hesitate to contact us. And we wish you all a good rest of the week.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…